Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Referee report. For: Case Report: Allogenic Wharton's jelly mesenchymal stem cell and exosome therapy are safe and effective for diabetic kidney failure [version 1; peer review: 1 not approved] — Giuseppe Remuzzi (2024) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Referee report. For: Case Report: Allogenic Wharton's jelly mesenchymal stem cell and exosome therapy are safe and effective for diabetic kidney failure [version 1; peer review: 1 not approved]
Shared by
Giuseppe Remuzzi
Referee report. For: Case Report: Allogenic Wharton's jelly mesenchymal stem cell and exosome therapy are safe and effective for diabetic kidney failure [version 1; peer review: 1 not approved]
Article
2024
en
Authors
Giuseppe Remuzzi
MC
Monica Cortinovis
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2021
Referee report. For: Philympics 2021: Prophage Predictions Perplex Programs [version 1; peer review: 1 approved with reservations]
Franklin L Nobrega
Article
2017
Referee report. For: A multi-disciplinary perspective on emergent and future innovations in peer review [version 2; referees: 1 approved, 1 approved with reservations]
David Moher
Article
2017
Referee report. For: A multi-disciplinary perspective on emergent and future innovations in peer review [version 1; referees: 1 approved with reservations]
David Moher
Article
2013
Referee report. For: Photodynamic therapy with new sublingual sensitiser Photosoft®E4 for cancer: a case series [v1; approved with reservations 1, not approved 1, http://f1000r.es/1en]
Michael R Hamblin
Preprint
2025
Referee report. For: A range of voltage-clamp protocol designs for rapid capture of hERG kinetics [version 2; peer review: 3 approved]
Davey L Jones
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.